Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_2

50%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

unknown1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

unknown125%

terminated125%

completed250%

Recent Activity

0 active trials

Showing 4 of 4

unknownphase_2

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

NCT02576561

completedphase_1

Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer

NCT00016146

completedphase_1

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

NCT00329368

terminatedphase_2

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

NCT00485563

Clinical Trials (4)

Showing 4 of 4 trials

NCT02576561Phase 2

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

Unknown

NCT00016146Phase 1

Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer

Completed

NCT00329368Phase 1

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Completed

NCT00485563Phase 2

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Terminated

All 4 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 4